Fundraising FoxAM Pharma
4 known investors
Find your way into AM Pharma
AM-Pharma develops ilofotase alfa, a recombinant alkaline phosphatase enzyme therapy, and is studying it as a treatment for adults with hypophosphatasia (HPP), a rare inherited metabolic bone disease. The company focuses on addressing the unmet need of adult-onset HPP patients who lack disease-specific treatment options.
Investors · 4
Kurma Partnerslisted by Kurma PartnersParis · $162K – $10.8M
How we know: Kurma Partners's portfolio page · a partner's Signal profile · the VCSheet dataset · Not right? Tell us
Ysios Capitallisted by Ysios CapitalBarcelona · $5.4M – $21.6M
How we know: Ysios Capital's portfolio page · a partner's Signal profile · the VCSheet dataset · Not right? Tell us
ForbionreportedNaarden
How we know: a partner's Signal profile · Not right? Tell us
Founder mafia
2 people who came through AM Pharma went on to found or lead other companies.
In the news
Frequently asked questions
- What does AM Pharma do?
- AM-Pharma develops ilofotase alfa, a recombinant alkaline phosphatase enzyme therapy, and is studying it as a treatment for adults with hypophosphatasia (HPP), a rare inherited metabolic bone disease. The company focuses on addressing the unmet need of adult-onset HPP patients who lack disease-specific treatment options.
- Who are AM Pharma's investors?
- AM Pharma's investors include Andera Partners, Kurma Partners, Ysios Capital, Forbion.